escape her-family tyrosine kinase inhibitor therapy kinase-inactive her3
oncogenic tyrosine kinases proved promising targets development highly effective anticancer drugs however tyrosine kinase inhibitors tkis human epidermal growth factor receptor family show limited activity her2-driven breast cancers despite effective inhibition epidermal growth factor receptor egfr her2 vivo- reasons unclear signalling trans key feature multimember family critically important phosphatidylinositol- oh kinase pi k/akt pathway driven predominantly transphosphorylation kinase-inactive her3 refs show her3 consequently pi k/akt signalling evade inhibition current her-family tkis vitro tumours vivo due compensatory shift her3 phosphorylation dephosphorylation equilibrium driven increased membrane her3 expression driving phosphorylation reaction reduced her3 phosphatase activity impeding dephosphorylation reaction compensatory changes driven akt-mediated negative-feedback signalling although her3 direct target tkis her3 substrate resistance undermines efficacy thus far gone undetected experimental abrogation her3 resistance small interfering rna knockdown restores potent pro-apoptotic activity otherwise cytostatic tkis re-affirming oncogene-addicted nature her2-driven tumours therapeutic promise oncoprotein target however her3 signalling buffered incomplete inhibition her2 kinase much potent tkis combination strategies required silence oncogenic her2 signalling effectively biologic marker assess efficacy tkis transphosphorylation her3 rather autophosphorylation
